|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Management and outcome of hepatocellular adenoma with massive bleeding at presentation显示文摘AIM To evaluate outcome of acute management and risk of rebleeding in patients with massive hemorrhage due to hepatocellular adenoma(HCA). METHODS This retrospective cohort study included all consecutive patients who presented to our hospital with massive hemorrhage(grade Ⅱ or Ⅲ) due to ruptured HCA and were admitted for observation and/or intervention between 1999-2016. The diagnosis of HCA was based on radiological findings from contrastenhanced magnetic resonance imaging(MRI) or pathological findings from biopsy or resection of the HCA. Hemorrhage was diagnosed based on findings from computed tomography or MRI. Medical records were reviewed for demographic features, clinical presentation, tumor features, initial and subsequent management, short-and long-term complications and patient and lesion follow-up. RESULTS All patients were female(n = 23). Treatment in the acute phase consisted of embolization(n = 9, 39.1%), conservative therapy(n = 13, 56.5%), andother intervention(n = 1, 4.3%). Median hemoglobin level decreased significantly more on days 0-3 in the intervention group than in the patients initially treated conservatively(0.9 mmol/L vs 2.4 mmol/L respectively, P = 0.006). In total, 4 patients suffered severe shortterm complications, which included hypovolemic shock, acute liver failure and abscess formation. After a median follow-up of 36 mo, tumor regression in nonsurgically treated patients occurred with a median reduction of 76 mm down to 25 mm. Four patients underwent secondary(elective) treatment(i.e., tumor resection) to address HCA size of > 5 cm and/or desire for future pregnancy. One case of rebleeding was documented(4.3%). None of the patients experienced long-term complication(mean follow-up time: 36 mo). CONCLUSION With a 4.3% risk of rebleeding, secondary(elective) treatment of HCA after massive hemorrhage may only be considered in patients with persistent HCA > 5 cm. | Anne J Klompenhouwer Robert A de Man Maarten GJ Thomeer Jan NM Ijzermans | 2017 | World Journal of Gastroenterology2017，23，25： | 5 |
| 2 | lnhibition of DPP-4 with sitag {ip tin improves glycemic control and restoresi~leteellm a~sand function in a rodent odel of type 2 diabetes显示文摘 | Mu J Petrov A Eierm ann GJ | 2009 | EurJPharmac ol2009，，： | 1 |
| 3 | An in vitro method for studying the proliferation and differentiation of Atlantic salmon preadipocytes显示文摘 | Anne Vegusdal Hilde Sundvold Tor Gj?en Bente Ruyter | 2003 | Lipids2003，，3： | 1 |
| 4 | Top 10 plant-parasitic nematodes in molecular plant pathology显示文摘 | John TJ Annelies H Etienne GJ | 2013 | Molecular Plant Pathology2013，14，： | 1 |
| 5 | A retrospective clinicopatholo-cal study of 37 patients with chordoma: a Danish national series 显示文摘 | Akmal S Ole SN Anne GJ | 1997 | Sarcoma1997，1，： | 1 |
| 6 | 肝移植术后长期生存率在过去30年期间未取得显著提高显示文摘背景:过去35年原位肝移植术(Orthotopic liver transplantation)后短期生存率取得了显著提高,以钙调磷酸酶抑制剂为基础的免疫抑制方案问世后不久,患者术后1年生存率约为65%。30年后美国患者术后1年平均生存率超过92%。然而,多项已发表的研究显示同一时期患者术后长期生存率仅略有提高。 | Decades Rana A Ackah RL Webb GJ Halazun KJ Vierling JM Ann Surg 方翊天 吴若林 | 2019 | 肝胆外科杂志2019，27，1： | 1 |
| 7 | 控制心脏和肝脏移植显示文摘前言器官移植自开始以来,就一直是健康律师们所热衷的话题。美国50州在实行统一解剖授予法案后,随之而来的便是如何获得器官的问题。但是,由于器官移植中主要问题实质上是不合法的,因而解决这些问题的方法也是不合法的,这目前已很明显。心和肝移植是极端昂贵的医疗手段,几乎没有任何个人能够支付这笔费用,也很少有医院能开展此类手术,在经济萧条时期,怎么能将器官移植和其它极端昂贵的治疗方法引进健康保健的供给系统呢? 由联邦政府建立少量高质量的器官移植中心,这种要求貌似合理。 | Annes GJ 周晓松 | 1990 | 国外医学(卫生经济分册)1990，7，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员